Korean Circ J.  1975 Jun;5(1):31-35. 10.4070/kcj.1975.5.1.31.

Clinical Evaluation of Alpha-Acetyldigoxin in Patients with Congestive Heart Failure

• Yoo SH
• Chang R
• Park YB
• Seo J
• Lee YW
• Lee SH

• KMID: 1667822
• DOI: http://doi.org/10.4070/kcj.1975.5.1.31

Abstract

The results of alpha-acetyldigoxin(Dioxanin(R)) administration in 21 patients with congestive heart failure were as follows. Alpha-acetyldigoxin is a new oral preparation of cardiac glycoside derived from lanatosid C. 1. For rapid digitalization in 2-3 days, the initial dose was 1.2 to 2.6mg (average 1.96mg). For medium-fast digitalization in 4 days, the loading dose was 2.0 to 3.2mg (average 2.7mg). For slow digitalization 0.1 to 0.4mg was required for 5 to 6 days without loading dose. The maintenance dose was 0.1 to 0.4mg (average 0.33mg) daily. 2. The therapeutic effect of acetyldigoxin was excellent in 15 cases (71%), good in 4 cases (20%) and stationary in 2 cases (9%). 3. Side effects were observed in 2 cases with usual dosage regimen. One accidental case who took single dose of 4mg(20 tablests) developed supraventricular tachycardia with varying degree of atrioventricular block, ventricular bigeminy and premature beat but recovered completely after 6 days.

MeSH Terms

Acetyldigoxins*
Atrioventricular Block
Cardiac Complexes, Premature
Estrogens, Conjugated (USP)*
Heart Failure*
Humans
Tachycardia, Supraventricular
Acetyldigoxins
Estrogens, Conjugated (USP)